Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (281-290 of 314) with videos related to

Pageof 32
Sort By:
The Lancet. Oncology|May 10, 2017
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomasMichael Weller, Martin van den Bent, Jörg C Tonn, et al.
Research Square|October 3, 2025
Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205Derek Wainwright, Rimas Lukas, Lijie Zhai, et al.
The Lancet. Oncology|August 1, 2017
Evidence-based management of adult patients with diffuse glioma - Authors' replyMichael Weller, Martin van den Bent, Jörg C Tonn, et al.
JAMA Oncology|January 19, 2017
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, et al.
Neuro-Oncology|April 4, 2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOGDeborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR TrialMichael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
The Lancet. Digital Health|October 24, 2021
Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort studyChandrakanth Jayachandran Preetha, Hagen Meredig, Gianluca Brugnara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
JAMA|December 21, 2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew Kanner, et al.
The Journal of Clinical Investigation|August 29, 2024
B cell-based therapy produces antibodies that inhibit glioblastoma growthSi Wang, Brandyn A Castro, Joshua L Katz, et al.
Pageof 32

Showing results (281-290 of 314) with videos related to

Sort By:
Pageof 32
The Lancet. Oncology|May 10, 2017
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomasMichael Weller, Martin van den Bent, Jörg C Tonn, et al.
Research Square|October 3, 2025
Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205Derek Wainwright, Rimas Lukas, Lijie Zhai, et al.
The Lancet. Oncology|August 1, 2017
Evidence-based management of adult patients with diffuse glioma - Authors' replyMichael Weller, Martin van den Bent, Jörg C Tonn, et al.
JAMA Oncology|January 19, 2017
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, et al.
Neuro-Oncology|April 4, 2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOGDeborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR TrialMichael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
The Lancet. Digital Health|October 24, 2021
Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort studyChandrakanth Jayachandran Preetha, Hagen Meredig, Gianluca Brugnara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
JAMA|December 21, 2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew Kanner, et al.
The Journal of Clinical Investigation|August 29, 2024
B cell-based therapy produces antibodies that inhibit glioblastoma growthSi Wang, Brandyn A Castro, Joshua L Katz, et al.
Pageof 32